Komipharm International Co. Ltd (041960) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.002x

Based on the latest financial reports, Komipharm International Co. Ltd (041960) has a cash flow conversion efficiency ratio of -0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-178.43 Million ≈ $-120.92K USD) by net assets (₩74.86 Billion ≈ $50.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Komipharm International Co. Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Komipharm International Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Komipharm International Co. Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Komipharm International Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Komipharm International Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Future Generation Australia Ltd AU:FGX	0.126x
VTEX NYSE:VTEX	0.034x
Puma Biotechnology Inc NASDAQ:PBYI	0.111x
Nexxen International Ltd NASDAQ:NEXN	0.087x
Hyundai Motor S3 Pref KO:005389	-0.039x
Berjaya Corporation Bhd KLSE:3395	-0.018x
Rajesh Exports Limited NSE:RAJESHEXPO	0.052x
I.C.C. International Public Company Limited BK:ICC	0.004x

Annual Cash Flow Conversion Efficiency for Komipharm International Co. Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Komipharm International Co. Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Komipharm International Co. Ltd stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩65.54 Billion ≈ $44.41 Million	₩8.85 Billion ≈ $6.00 Million	0.135x	+389.35%
2023-12-31	₩60.02 Billion ≈ $40.67 Million	₩-2.80 Billion ≈ $-1.90 Million	-0.047x	-56.46%
2022-12-31	₩60.63 Billion ≈ $41.09 Million	₩-1.81 Billion ≈ $-1.23 Million	-0.030x	-57.78%
2021-12-31	₩66.46 Billion ≈ $45.04 Million	₩-1.26 Billion ≈ $-851.13K	-0.019x	-5819.79%
2020-12-31	₩76.28 Billion ≈ $51.69 Million	₩25.20 Million ≈ $17.08K	0.000x	-97.45%
2019-12-31	₩73.28 Billion ≈ $49.66 Million	₩950.79 Million ≈ $644.34K	0.013x	+160.06%
2018-12-31	₩93.39 Billion ≈ $63.29 Million	₩-2.02 Billion ≈ $-1.37 Million	-0.022x	-1028.56%
2017-12-31	₩101.27 Billion ≈ $68.63 Million	₩235.64 Million ≈ $159.69K	0.002x	-82.06%
2016-12-31	₩93.20 Billion ≈ $63.16 Million	₩1.21 Billion ≈ $819.00K	0.013x	+133.70%
2015-12-31	₩76.13 Billion ≈ $51.59 Million	₩-2.93 Billion ≈ $-1.98 Million	-0.038x	+19.33%
2014-12-31	₩53.16 Billion ≈ $36.02 Million	₩-2.54 Billion ≈ $-1.72 Million	-0.048x	-154.21%
2013-12-31	₩44.72 Billion ≈ $30.31 Million	₩3.93 Billion ≈ $2.67 Million	0.088x	--

About Komipharm International Co. Ltd

KQ:041960 Korea Pharmaceuticals

Market Cap

$380.81 Million

₩561.93 Billion KRW

Market Cap Rank

#13908 Global

#471 in Korea

Share Price

₩9720.00

Change (1 day)

-2.11%

52-Week Range

₩5060.00 - ₩10310.00

All Time High

₩43026.96